Hui Liu

Hui Liu

Auto-generated profile, based on publicly available information

Hui Liu

Department of Pathology, Qilu Hospital, Shandong University, Jinan, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
LGLin Gao
Lin Gao
BWBaozhen Wang
Baozhen Wang
HLHui Liu
Hui Liu
PLPing Liu
Ping Liu
LLLong Liu
Long Liu
BHBo Han
Bo Han
Background: Although immunotherapy has revolutionized cancer treatment, its efficacy in castration-resistant prostate cancer (CRPC) remains limited, largely due to an immunologically “cold” tumor microenvironment with scarce T-cell infiltration. Unraveling the molecular mechanisms underlying immune evasion and developing novel strategies to activate innate antitumor immunity are therefore critical to overcoming immunotherapy resistance in CRPC. Methods: Using bioinformatic approaches, we analyzed the protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1) expression and its correlation with immune cell infiltration and response to immune checkpoint blockade (ICB) in public databases. PKMYT1 protein expression was further evaluated via immunohistochemistry in a clinical cohort of prostate cancer (PCa) specimens. Mechanistic investigations were conducted in PCa cell lines and mouse models. The immunological impact of PKMYT1 inhibition was delineated using single-cell RNA sequencing, and the therapeutic efficacy of RP-6306, either as monotherapy or in combination with programmed death-ligand 1 (PD-L1) blockade, was evaluated in syngeneic mouse models. Results: PKMYT1 expression was significantly overexpressed in CRPC compared with primary PCa. High PKMYT1 expression correlated with a suppressed antitumor immunity and poor clinical response to ICB. Mechanistically, PKMYT1 inhibition activated the cyclic guanosine monophosphate-adenosine monophosphate adenosine synthase (cGAS)-stimulator of interferon genes (STING) pathway, potentiated both type I and II interferon signaling, and upregulated chemokines, including CCL5 and CXCL10. The selective PKMYT1 inhibitor, RP-6306, enhanced the efficacy of ICB in the presence of CD8 + T cells. Treatment with a PKMYT1 inhibitor alone or in combination with PD-L1 blockade significantly increased the infiltration of activated CD8 + T cells and induced significant tumor suppression in vivo. Conclusion: PKMYT1 is a pivotal dual regulator of tumor progression and immune evasion in CRPC. Our findings provide a compelling preclinical rationale for targeting PKMYT1 as a novel strategy to reprogram the tumor immune microenvironment and overcome resistance to immunotherapy.

1 October 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
FSFeifei Sun
Feifei Sun
LGLin Gao
Lin Gao
MWMeng Wang
Meng Wang
PLPing Liu
Ping Liu
BWBaozhen Wang
Baozhen Wang
BHBo Han
Bo Han
Molecular-based risk stratification of prostate cancer holds significant potential for guiding precision therapeutic strategies. Previous studies revealed that SOX4 activation drives prostate cancer progression in PTEN-deficient tumors through the PI3K-AKT signaling pathway. However, the mechanistic interplay between SOX4 and PTEN, as well as their clinical utility for prognostic stratification, remains to be elucidated. In this study, we revealed that SOX4 expression is increased in patients with prostate cancer with low PTEN levels, and the expression of SOX4 and PTEN is inversely correlated in patients with prostate cancer. Importantly, patients with prostate cancer exhibiting SOX4-high/PTEN-low (SOX4+/PTEN−) expression represent an aggressive prostate cancer subtype associated with an unfavorable prognosis. Mechanistically, we found that SOX4 downregulates PTEN protein expression at the post-transcriptional level. Through high-throughput miRNA profiling and bioinformatics analysis, we identified that SOX4 transcriptionally activates the expression of the miR-106b∼25 cluster, which directly targets PTEN. Furthermore, SOX4 overexpression combined with PTEN deficiency leads to hyperactivation of the PI3K-AKT pathway. Importantly, dual targeting of SOX4 and PI3K-AKT signaling effectively suppresses prostate cancer cell proliferation, migration, and invasion in vivo and in vitro. These data establish a novel SOX4/miR-106b∼25/PTEN pathway model in promoting prostate cancer progression and propose a potential therapeutic strategy for this high-risk subtype. Implications: SOX4 suppresses PTEN through the transcriptional upregulation of miR-106b∼25, rendering tumors sensitive to combined inhibition of SOX4 and PI3K-AKT in prostate cancer.

17 June 2026
Verified
Other
Open access
FSFeifei Sun
Feifei Sun
BWBaozhen Wang
Baozhen Wang
SMShuyu Mei
Shuyu Mei
LZLin Zhang
Lin Zhang
WXWang Xinpei
Wang Xinpei
XWXueli Wang
Xueli Wang
Immune cell infiltration in prostate cancer tissues before and after NADT.

17 June 2026
Verified
Other
Open access
FSFeifei Sun
Feifei Sun
BWBaozhen Wang
Baozhen Wang
SMShuyu Mei
Shuyu Mei
LZLin Zhang
Lin Zhang
WXWang Xinpei
Wang Xinpei
XWXueli Wang
Xueli Wang
FOSL2 and PD-L1 protein expression in NADT-sensitive and -resistant prostate cancer before and after NADT.

17 June 2026
Verified
Other
Open access
FSFeifei Sun
Feifei Sun
BWBaozhen Wang
Baozhen Wang
SMShuyu Mei
Shuyu Mei
LZLin Zhang
Lin Zhang
WXWang Xinpei
Wang Xinpei
XWXueli Wang
Xueli Wang
FOSL2 expression in PCa cell lines.

17 June 2026
Verified
Other
Open access
FSFeifei Sun
Feifei Sun
BWBaozhen Wang
Baozhen Wang
SMShuyu Mei
Shuyu Mei
LZLin Zhang
Lin Zhang
WXWang Xinpei
Wang Xinpei
XWXueli Wang
Xueli Wang
Regulation of FOSL2 expression by androgen deprivation in prostate cancer cells.